Key result
A review of the 20-year clinical experience with the Hancock porcine bioprosthesis was conducted to evaluate its long-term durability and nonthrombogenicity, with no quantitative results reported.
Why the study?
Does the Hancock porcine bioprosthesis remain durable and nonthrombogenic over 20 years of clinical use in valve recipients?
Observational
Does the Hancock porcine bioprosthesis remain durable and nonthrombogenic over 20 years of clinical use in valve recipients?
Answers are grounded in this paper and cite their sources.
This report reviews 20 years of clinical experience with the Hancock porcine bioprosthesis to assess its long-term durability and safety.
The standard (glutaraldehyde-preserved) Hancock porcine bioprosthesis was introduced into clinical practice in order to provide surgeons with a cardiac valve substitute which would be nonthrombogenic and therefore would not require anticoagulation, and would be durable, anatomically suitable, and noiseless. In the present report we have reviewed our long-term experience with Hancock porcine valve recipients in order to verify the original expectations of this bioprosthesis have been met.
No takes yet. Share an insight, caveat, or question.
Bortolotti et al. (1992) conducted an observational in Cardiac valve replacement. Hancock porcine bioprosthesis was evaluated. A review of the 20-year clinical experience with the Hancock porcine bioprosthesis was conducted to evaluate its long-term durability and nonthrombogenicity, with no quantitative results reported.
Synapse has enriched 10 related papers. Consider them for comparative context: